YOLFTbeta
BioInvent International AB

BioInvent International AB

BINV · ST · Healthcare / Biotechnology

2.92SEK-0.00 (-0.17%)

Price History

Full chart

Market Stats

Previous Close2.92
Open2.92
Day Range2.71 – 3.02
52-Week Range19.22 – 34.85
Volume215.44K
Market Cap1.51B
P/E (TTM)0.00
Forward P/E4.77
EPS-7.56
Dividend Yield0.00%
Beta0.02
50-Day Avg23.12
200-Day Avg24.73

About

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Martin Welschof Ph.D.
  • Employees108
  • HeadquartersThe Gamma Building, Lund, Sweden, 223 70, Sweden
  • Websitehttps://www.bioinvent.com

Leadership

  • Dr. Martin Welschof Ph.D.President & CEO · b. 1961
  • Mr. Stefan Ericsson M.B.A.Chief Financial Officer · b. 1963
  • Mr. Kristoffer Rudenholm HanssonSenior Vice President of Technical Operations · b. 1974
  • Mr. Björn FrendéusChief Scientific Officer · b. 1973
  • Ms. Cecilia HofvanderVice President of Investor Relations · b. 1967
  • Dr. Andres McAllisterChief Medical Officer · b. 1956
  • Ms. Ingrid TeigeHead of Preclinical Research
  • Ms. Sylvie RyckebuschChief Business Officer · b. 1965
  • Dr. Ingunn Munch LindvigSenior Vice President of Regulatory Affairs · b. 1965
  • Mr. Ashley R. RobinsonSenior VP of Strategy & Finance · b. 1977

Financials

Income Statement

Currency: SEK2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue24.09M58.27M87.05M66.72M58.75M28.20M50.83M143.44M252.14M80.66M82.87M124.65M42.95M81.71M46.93M15.93M71.28M45.01M38.55M93.74M147.37M19.38M326.13M71.46M44.69M226.50M
Growth (%)-+141.87%+49.40%-23.36%-11.94%-52.00%+80.26%+182.20%+75.78%-68.01%+2.74%+50.42%-65.55%+90.27%-42.56%-66.07%+347.62%-36.85%-14.36%+143.18%+57.21%-86.85%+1582.45%-78.09%-37.47%+406.86%
Cost of Revenue22.45M36.48M46.10M-----------01.65M996.00K2.88M0-------
Gross Profit--87.05M66.72M58.75M28.20M50.83M143.44M252.14M80.66M82.87M124.65M42.95M81.71M46.93M14.28M70.29M42.13M38.55M93.74M147.37M19.38M326.13M71.46M44.69M226.50M
Gross Margin--100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%89.64%98.60%93.60%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense--24.64M-34.03M156.85M170.53M162.56M119.99M245.57M260.16M210.71M196.31M234.04M100.89M101.86M109.25M133.15M142.77M161.78M231.59M222.85M297.73M377.05M441.40M515.75M577.89M
Operating Income--62.42M100.75M-98.10M-142.33M-111.73M23.45M6.57M-179.50M-127.84M-71.66M-191.09M-19.18M-54.92M-94.97M-62.86M-100.63M-123.23M-137.85M-75.47M-278.35M-50.92M-369.94M-471.06M-351.39M
Operating Margin--71.70%151.01%-166.99%-504.77%-219.82%16.35%2.61%-222.54%-154.27%-57.49%-444.96%-23.47%-117.03%-596.38%-88.18%-223.56%-319.68%-147.05%-51.21%-1435.98%-15.61%-517.68%-1054.15%-155.14%
EBITDA---135.99M-148.59M-71.55M-119.55M-93.40M-4.67M27.85M-165.54M-117.48M-60.75M-182.36M-15.14M-51.94M-93.38M-61.59M-97.65M-118.10M-126.54M-63.99M-263.32M-27.13M-312.71M-409.38M-331.52M
EBITDA Margin---156.22%-222.73%-121.79%-423.96%-183.76%-3.26%11.04%-205.24%-141.77%-48.74%-424.62%-18.53%-110.68%-586.36%-86.40%-216.93%-306.36%-134.99%-43.42%-1358.42%-8.32%-437.59%-916.14%-146.37%
Net Income--46.17M89.66M-92.52M-139.86M-108.83M-16.09M16.25M-176.66M-128.40M-67.05M-187.84M-18.04M-53.98M-90.68M-62.59M-100.53M-123.16M-139.12M-76.67M-278.96M-34.09M-330.30M-429.38M-332.86M
Net Income Margin--53.03%134.39%-157.48%-496.00%-214.12%-11.22%6.45%-219.02%-154.95%-53.79%-437.40%-22.08%-115.03%-569.43%-87.80%-223.33%-319.51%-148.41%-52.02%-1439.13%-10.45%-462.22%-960.87%-146.96%
R&D23.18M45.26M111.68M131.05M126.09M122.68M120.52M140.86M215.43M229.19M178.89M163.90M207.28M71.18M73.37M80.50M99.48M109.72M140.18M207.90M191.42M258.34M325.93M390.43M457.73M504.22M
R&D as % of Total Revenue96.23%77.66%128.29%196.43%214.63%435.06%237.12%98.20%85.44%284.14%215.88%131.49%482.65%87.11%156.34%505.51%139.55%243.75%363.66%221.78%129.89%1332.73%99.94%546.36%1024.33%222.62%
Interest Expense0016.32M11.14M5.58M18.00K10.00K7.39M53.00K163.00K1.55M169.00K9.00K01.00K2.00K9.00K4.00K6.00K482.00K336.00K517.00K650.00K638.00K555.00K402.00K
Interest Expense % of Total Revenue0.00%0.00%18.75%16.70%9.50%0.06%0.02%5.15%0.02%0.20%1.87%0.14%0.02%0.00%0.00%0.01%0.01%0.01%0.02%0.51%0.23%2.67%0.20%0.89%1.24%0.18%

Balance Sheet

Currency: SEK2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets194.26M410.55M446.41M343.19M238.41M266.34M148.33M271.00M295.43M126.25M138.03M205.76M116.54M81.44M74.11M54.45M276.30M170.05M120.40M226.11M802.64M1.45B1.71B1.40B989.24M671.20M
Total Liabilities34.63M22.14M52.16M38.23M25.73M47.34M38.18M56.88M64.13M70.61M63.84M67.81M68.92M32.43M21.68M24.99M45.86M39.82M32.78M56.67M59.14M80.32M106.09M90.45M103.42M113.59M
Total Equity159.63M388.42M394.25M304.96M212.68M219.00M110.15M214.12M231.30M55.63M74.19M137.95M47.62M49.01M52.43M29.45M230.44M130.22M87.62M169.44M743.50M1.37B1.61B1.31B885.82M557.62M
Cash141.22M338.66M343.58M268.48M174.40M135.54M68.05M25.64M16.39M74.04M36.95M92.34M100.06M64.75M45.63M39.97M226.11M103.70M68.85M153.97M729.27M910.75M515.05M259.55M434.83M356.17M
Total Debt-------------------15.53M11.60M28.37M26.96M23.24M17.41M9.68M
Net Debt---343.58M-268.48M-174.40M-135.54M-68.05M-25.64M-16.39M-74.04M-36.95M-92.34M-100.06M-64.75M-45.63M-39.97M-226.11M-103.70M-68.85M-138.45M-717.67M-882.39M-488.08M-236.30M-417.41M-346.49M

Cash Flow

Currency: SEK2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---10.57M-66.25M-88.74M-105.48M-101.23M12.63M43.73M-127.14M-117.70M-55.45M-170.38M-54.65M-76.03M-72.57M-72.05M-75.88M-141.39M-125.43M-62.62M-245.84M-41.23M-341.69M-380.47M-247.75M
Investing Cash Flow---36.51M-9.23M-5.57M-20.42M-6.08M-3.91M-13.64M-1.30M-4.63M-4.92M-58.00K-47.00K-414.00K-672.00K-5.32M-16.48M-3.85M-3.84M-6.70M-467.54M-628.85M59.68M564.35M180.13M
Financing Cash Flow165.38M272.25M52.00M367.00K237.00K146.22M-120.12M--144.38M128.26M96.53M19.38M57.32M67.59M263.51M80.33M80.33M214.39M644.62M894.87M273.49M23.14M-8.46M-8.98M
Capital Expenditure13.85M25.62M36.51M9.23M5.57M23.36M8.96M3.91M13.64M1.30M4.63M4.92M58.00K47.00K414.00K672.00K5.32M16.48M3.85M3.84M6.70M13.26M12.38M13.30M10.03M7.26M
Free Cash Flow---47.08M-75.47M-94.31M-128.84M-110.19M8.72M30.09M-128.44M-122.33M-60.37M-170.44M-54.70M-76.44M-73.25M-77.37M-92.35M-145.24M-129.27M-69.32M-259.10M-53.60M-355.00M-390.50M-255.01M
FCF to OCF--445.43%113.93%106.27%122.15%108.85%69.04%68.81%101.02%103.93%108.86%100.03%100.09%100.54%100.93%107.39%121.72%102.72%103.06%110.70%105.39%130.02%103.89%102.64%102.93%

Earnings

Report DateMar 31, 2007Jun 30, 2007Sep 30, 2007Jun 30, 2008Sep 30, 2008Dec 31, 2008Mar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Apr 15, 2010Jul 14, 2010Oct 14, 2010Feb 10, 2011Apr 14, 2011Jul 14, 2011Oct 12, 2011Feb 9, 2012May 2, 2012Jul 19, 2012Oct 18, 2012Feb 21, 2013Apr 25, 2013Jul 25, 2013Oct 24, 2013Feb 20, 2014May 6, 2014Jul 24, 2014Oct 23, 2014Feb 18, 2015Apr 22, 2015Jul 22, 2015Oct 22, 2015Feb 17, 2016Apr 27, 2016Jul 26, 2016Oct 25, 2016Feb 15, 2017May 17, 2017Jul 26, 2017Oct 26, 2017Jan 30, 2018Apr 24, 2018Jul 24, 2018Oct 24, 2018Feb 25, 2019May 22, 2019Aug 22, 2019Oct 24, 2019Feb 27, 2020Apr 28, 2020Aug 27, 2020Oct 29, 2020Feb 23, 2021Apr 28, 2021Aug 26, 2021Oct 28, 2021Feb 23, 2022Apr 27, 2022Aug 25, 2022Oct 27, 2022Feb 22, 2023Apr 26, 2023Aug 30, 2023Oct 26, 2023Feb 22, 2024Apr 24, 2024Aug 29, 2024Oct 31, 2024Feb 28, 2025Apr 29, 2025Aug 26, 2025Oct 29, 2025Feb 26, 2026Apr 29, 2026Aug 27, 2026
EPS Estimate-------------11.50-5.00--10.00-22.50-21.12-18.25-16.25-13.37-------------------------2.71--1.66-1.96-1.86------1.13-1.71-1.37-1.67-1.16-1.17-1.25-1.27-1.27-1.24-1.11---------1.90-1.90
EPS Actual29.54-13.11-6.5045.92-10.97-15.62-11.95-18.41-14.66-15.77-11.89-7.14-10.25-17.2518.52-12.50-13.25-22.00-13.75-31.50-12.50-5.74-3.72-2.46-3.674.64-4.300.82-1.87-5.17-3.95-4.31-3.15-2.940.05-2.45-2.47-0.59-1.80-1.89-1.72-2.68-1.96-3.02-1.56-2.25-1.85-1.75-1.75-2.00-0.07-0.07-0.040.72-1.94-0.98-1.07-1.35-1.162.86-1.00-1.21-1.12-1.34-1.08-1.48-1.18-2.09-1.48-1.78-1.770.59-1.96-1.91-1.81-1.87
Surprise------------10.87%-245.00%--25.00%41.11%-4.17%24.66%-93.85%6.51%------------------------16.97%--5.42%10.71%-7.53%-----13.27%37.43%1.46%30.54%346.55%14.53%3.20%11.81%-5.72%12.90%-33.33%--------4.74%1.58%
Timing------------After-hoursPre-market-After-hoursAfter-hours-Pre-marketPre-marketPre-market-------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketAfter-hoursAfter-hours-Pre-marketPre-market

Key Statistics & Ratios

Market Cap1.51B
Enterprise Value1.14B
Trailing P/E0.00
Forward P/E4.77
PEG Ratio0.27
Price / Sales46.35
Price / Book4.60
EPS-7.56
Book Value4.82
Revenue (TTM)32.51M
Gross Profit (TTM)32.51M
EBITDA-498.82M
Profit Margin0.00%
Operating Margin-980.60%
Return on Equity-88.14%
Return on Assets-47.50%
Shares Outstanding65.80M
Shares Float31.44M
Beta0.02
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Dec 14, 20201:25
  • Jul 15, 202057:56
  • Mar 22, 2019741:739
  • Mar 21, 201627:25
  • Apr 23, 20151169:1056
  • Mar 20, 2014325:306
  • Mar 12, 2012143:142
  • Nov 8, 2005584:545